Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • ALGS (NCM)

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

800 466 6059 One Corporate Drive, South San Francisco, CA 94080, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know - Nasdaq
Nasdaq • Aug 19
Aligos Therapeutics provides update on ALG-000184 for chronic hepatitis B - European AIDS Treatment Group
European AIDS Treatment Group • Aug 14
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Yahoo Finance • Aug 6
Aligos Therapeutics Stock Rockets 57% With 7-Day Winning Streak - Trefis
Trefis • Nov 25
Aligos Therapeutics (Nasdaq: ALGS) details Phase 2 HBV progress and reports $99.1M cash - Stock Titan
Stock Titan • Nov 6

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Aligos Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Aligos Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has approximately 70 employees.
What industry is Aligos Therapeutics, Inc. in?
Aligos Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Aligos Therapeutics, Inc. a publicly traded company?
Yes, Aligos Therapeutics, Inc. is publicly traded under the ticker symbol ALGS on the NCM. The company has a market capitalization of approximately $0.06 billion.
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc. is headquartered in South San Francisco, CA, United States at One Corporate Drive, South San Francisco, CA 94080, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.